Cover Image
市場調查報告書

PharmaPoint:克隆氏症 - 全球醫藥品的預測與市場分析

PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298050
出版日期 內容資訊 英文 305 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:克隆氏症 - 全球醫藥品的預測與市場分析 PharmaPoint: Crohn's Disease - Global Drug Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 305 Pages
簡介

克隆氏症(CD)治療藥市場由於新生物療法的出現而非常活絡。由於抗TBF上市藥專利的到期,造成新興生技仿製藥的興起。譬如Remicade的生技仿製藥、Hospira的Inflectra(infliximab)等。

本報告提供全球克隆氏症(CD)治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 症狀
  • 預測
  • 生活品質(QOL)

第4章 流行病學

  • 危險因素和共生病症
    • 最大60%的CD患者經歷過骨骼密度低
    • 3分之一的CD患者患有精神疾病
    • 25%的CD患者關節炎發病
    • 部分CD患者也頻繁併發腸胃疾病
  • 全球趨勢
    • 美國
    • 歐洲5個國家
    • 日本
    • 加拿大
    • 中國
    • 印度
  • 預測手法
  • 利用之資訊來源
  • 預測的前提條件與手法
  • CD的流行病學預測
  • 議論
  • 分析的限制
  • 分析的優勢

第5章 疾病的管理

  • 治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大
  • 中國
  • 印度

第6章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
  • 生技仿製藥

第7章 機會及未滿足需求

  • 概要
  • 個別治療用生物標記的需求
  • 抗TNF難治型患者的治療
  • 未滿足需求的差距分析
  • 標靶治療
  • 早期診斷·治療的預測工具

第8章 開發平台評估

  • 概要
  • 臨床實驗設計
  • 臨床實驗:Phase別·各階段
  • 臨床開發中的潛力藥物
  • 其他後期開發中產品

第9章 現在/未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介
    • Johnson & Johnson
    • AbbVie
    • UCB
    • Biogen Idec
    • 武田藥品工業
    • ChemoCentryx

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本
  • 加拿大
  • 中國
  • 印度

第11章 附錄

圖表

目錄
Product Code: GDHC77PIDR

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon, such as -

  • Takeda's alpha4beta7 inhibitor, Entyvio (vedolizumab)
  • Johnson & Johnson's (J&J's) interleukin (IL)-12/23 inhibitor, Stelara (ustekinumab)

These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).

The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Patent expiries begin in 2015 for the current market leaders -

  • J&J's Remicade (infliximab)
  • AbbVie's Humira (adalimumab)

Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Exciting times lay ahead for the CD marketplace, as the market events noted above are due to occur against the backdrop of a steadily rising global CD prevalent population. With the clinical unmet need for better diagnostic tools and treatment options for the anti-TNF-refractory population, CD represents an attractive autoimmune disease for drug developers. This, in turn should fuel commercial interest in this subtype of IBD.

Highlights

Key Questions Answered

  • How will the CD market (sales and patient numbers) evolve over the 10-year forecast period from 2012 to 2022?
  • Which brands and specific drug classes did physicians select for their CD patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
  • How will the launch of late-stage pipeline therapies such as Entyvio and Stelara shape the future treatment landscape?
  • What are the remaining unmet needs and opportunities for drug developers within the CD market?

Key Findings

  • The main drivers of growth in the CD market during the coming decade include the anticipated launch of the first non-anti-tumor necrosis factor (TNF) biologics, Entyvio and Stelara; the uptake of infliximab and adalimumab biosimilars; and the increasing prevalent cases of CD.
  • Companies striving to enter the CD market appear most focused on the anti-TNF refractory population, as this remains the most underserved group. However, competition within this patient segment is set to intensify from 2014 on, following new product launches. Therefore, companies with early-phase products targeting this patient group may struggle to gain a foothold in the future CD market.
  • The level of unmet need in the CD marketplace is moderate, with clinical unmet needs being the main driver for research into this autoimmune disease. The most pressing clinical unmet need is for reliable disease diagnostic tools, such as biomarkers, as these could aid physicians to tailor their treatment approach.
  • Although GlobalData forecasts four new product launches (Entyvio, Stelara, vercirnon, and Prochymal [remestemcel-L]) during the 2012-2022 forecast period, growth within the 10 CD healthcare markets covered in this report will largely be driven by the strong uptake of Entyvio and Stelara.

Scope

  • Overview of CD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized CD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the CD therapeutics markets.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-to-late stage pipeline drugs.
  • Analysis of the current and future market competition in the global CD therapeutics markets. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global CD therapeutics markets.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CD therapeutics markets in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global CD therapeutics markets from 2012-2022.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Risk Factors and Comorbidities
    • 4.1.1. Up to 60% of CD patients experience reduced bone density
    • 4.1.2. One third of patients with CD suffer from psychiatric illness
    • 4.1.3. Arthritis affects 25% of CD Patients
    • 4.1.4. Gastrointestinal complications often occur as part of CD
  • 4.2. Global Trends
    • 4.2.1. US
    • 4.2.2. 5EU
    • 4.2.3. Japan
    • 4.2.4. Canada
    • 4.2.5. China
    • 4.2.6. India
  • 4.3. Forecast Methodology
  • 4.4. Sources Used
    • 4.4.1. US
    • 4.4.2. France
    • 4.4.3. Germany
    • 4.4.4. Italy
    • 4.4.5. Spain
    • 4.4.6. UK
    • 4.4.7. Japan
    • 4.4.8. Canada
    • 4.4.9. China
    • 4.4.10. India
  • 4.5. Forecast Assumptions and Methods
    • 4.5.1. Incident Cases
    • 4.5.2. Prevalent Cases
    • 4.5.3. Sources Not Used
  • 4.6. Epidemiological Forecast for CD
    • 4.6.1. Incident Cases of CD
    • 4.6.2. Prevalent Cases of CD
  • 4.7. Discussion
  • 4.8. Limitations of the Analysis
  • 4.9. Strengths of the Analysis

5. Disease Management

  • 5.1. Treatment Overview
  • 5.2. US
    • 5.2.1. Diagnosis
    • 5.2.2. Clinical Practice
  • 5.3. France
    • 5.3.1. Diagnosis
    • 5.3.2. Clinical Practice
  • 5.4. Germany
    • 5.4.1. Diagnosis
    • 5.4.2. Clinical Practice
  • 5.5. Italy
    • 5.5.1. Diagnosis
    • 5.5.2. Clinical Practice
  • 5.6. Spain
    • 5.6.1. Diagnosis
    • 5.6.2v Clinical Practice
  • 5.7. UK
    • 5.7.1. Diagnosis
    • 5.7.2. Clinical Practice
  • 5.8. Japan
    • 5.8.1. Diagnosis
    • 5.8.2. Clinical Practice
  • 5.9. Canada
    • 5.9.1. Diagnosis
    • 5.9.2. Clinical Practice
  • 5.10. China
    • 5.10.1. Diagnosis
    • 5.10.2. Clinical Practice
  • 5.11. India
    • 5.11.1. Diagnosis
    • 5.11.2. Clinical Practice

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Strategic Competitor Assessment
  • 6.3. Product Profiles - Major Brands
    • 6.3.1. Remicade (infliximab)
    • 6.3.2. Humira (adalimumab)
    • 6.3.3. Cimzia (certolizumab pegol)
    • 6.3.4. Tysabri (natalizumab)
    • 6.3.5. Other Marketed Products
  • 6.4. Biosimilars
    • 6.4.1. Introduction
    • 6.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 6.4.3. Biosimilars in the Immunology Community
    • 6.4.4. By the Numbers: Biosimilars in Development
    • 6.4.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry
    • 6.4.6. Biosimilars' Forecast

7. Opportunity and Unmet Need

  • 7.1. Overview
  • 7.2. Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach
  • 7.3. More Therapies for Anti-TNF-Refractory Patients
  • 7.4. Unmet Needs Gap Analysis
  • 7.5. Targeted Therapies
  • 7.6. Predictive Tools for Early Diagnosis and Treatment

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Country
  • 8.3. Clinical Trials by Phase and Trial Status
  • 8.4. Promising Drugs in Clinical Development
    • 8.4.1. Entyvio (vedolizumab)
    • 8.4.2. Stelara (ustekinumab)
    • 8.4.3. Vercirnon (formerly GSK1605786)
    • 8.4.4. Prochymal (Remestemcel-L)
  • 8.5. Other Late-Stage Pipeline Products
    • 8.5.1. Cx601
    • 8.5.2. RHB-104 (clarithromycin + clofazimine + rifabutin)

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Johnson & Johnson
    • 9.3.2. AbbVie
    • 9.3.3. UCB
    • 9.3.4. Biogen Idec
    • 9.3.5. Takeda
    • 9.3.6. ChemoCentryx

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. Canada
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. China
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers
  • 10.11. India
    • 10.11.1. Forecast
    • 10.11.2. Key Events
    • 10.11.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed CD Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Individual Drug Assumptions
    • 11.4.7. Generic Erosion
    • 11.4.8. Pricing of Pipeline agents
  • 11.5. Physicians and Specialists Included in This Study
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Author/Reviewer
    • 11.7.2. Epidemiologist
    • 11.7.3. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Symptoms of CD
  • Table 2: Comorbidities for CD
  • Table 3: Sources of Incidence Data Used in This Analysis
  • Table 4: Sources of Prevalence Data Used in This Analysis
  • Table 5: All Markets, Incident Cases of CD, Ages ≥10 Years, Men and Women, N, 2012-2022
  • Table 6: All Markets, Incident Cases of CD, by Age, Men and Women, N (Row Total), 2012
  • Table 7: All Markets, Incident Cases of CD, by Sex, Ages ≥10 Years, N (%), 2012
  • Table 8: All Markets, Prevalent Cases of CD, Ages ≥10 Years, Men and Women, N, 2012-2022
  • Table 9: All Markets, Prevalent Cases of CD, by Age, Men and Women, N, 2012
  • Table 10: All Markets, Prevalent Cases of CD, by Sex, Ages ≥10 Years, N (%), 2012
  • Table 11: Treatment Guidelines for CD
  • Table 12: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013
  • Table 13: Leading Branded Drugs Used to Treat CD
  • Table 14: Product Profile - Remicade
  • Table 15: Remicade SWOT Analysis, 2013
  • Table 16: Global Sales Forecasts ($) for Remicade, 2012-2022
  • Table 17: Product Profile - Humira
  • Table 18: Humira SWOT Analysis, 2013
  • Table 19: Global Sales Forecasts ($) for Humira, 2012-2022
  • Table 20: Product Profile - Cimzia
  • Table 21: Cimzia SWOT Analysis, 2013
  • Table 22: Global Sales Forecasts ($) for Cimzia, 2012-2022
  • Table 23: Product Profile - Tysabri
  • Table 24: Tysabri SWOT Analysis, 2013
  • Table 25: Global Sales Forecasts ($) for Tysabri, 2012-2022
  • Table 26: Summary of the Minor Therapeutic Classes in CD, 2013
  • Table 27: Biosimilars Pipeline, 2013
  • Table 28: Global Sales Forecasts ($) for Infliximab Biosimilars, 2012-2022
  • Table 29: Global Sales Forecasts ($) for Adalimumab Biosimilars, 2012-2022
  • Table 30: Global Sales Forecasts ($) for Certolizumab pegol Biosimilars, 2012-2022
  • Table 31: Overall Unmet Needs in CD - Current Level of Attainment
  • Table 32: Clinical Unmet Needs in CD - Gap Analysis, 2013
  • Table 33: CD - Clinical Trials by Phase and Status, 2013
  • Table 34: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013
  • Table 35: Comparison of Therapeutic Classes in Development for CD, 2013
  • Table 36: Product Profile - Entyvio
  • Table 37: Efficacy of Entyvio in GEMINI II Studies of CD
  • Table 38: Entyvio SWOT Analysis, 2013
  • Table 39: Global Sales Forecasts ($) for Entyvio, 2012-2022
  • Table 40: Product Profile - Stelara
  • Table 41: Comparison of Stelara's Phase IIb CERTIFI trial Efficacy Data Versus Tysabri's Phase III Efficacy Data in Anti-TNF Refractory CD Patients
  • Table 42: Stelara SWOT Analysis, 2013
  • Table 43: Global Sales Forecasts ($) for Stelara, 2012-2022
  • Table 44: Product Profile - Vercirnon
  • Table 45: Vercirnon SWOT Analysis, 2013
  • Table 46: Global Sales Forecasts ($) for Vercirnon, 2012-2022
  • Table 47: Product Profile - Prochymal
  • Table 48: Prochymal SWOT Analysis, 2013
  • Table 49: Global Sales Forecasts ($) for Prochymal, 2012-2022
  • Table 50: Product Profile - Cx601
  • Table 51: Cx601 SWOT Analysis, 2013
  • Table 52: Product Profile - RHB-104
  • Table 53: RHB-104 SWOT Analysis, 2013
  • Table 54: Key Companies in the CD Market, 2013
  • Table 55: J&J's CD Portfolio Assessment, 2013
  • Table 56: J&J's CD SWOT Analysis, 2013
  • Table 57: AbbVie's CD Portfolio Assessment, 2013
  • Table 58: Abbott/AbbVie's CD SWOT Analysis, 2013
  • Table 59: UCB's CD Portfolio Assessment, 2013
  • Table 60: UCB's CD SWOT Analysis, 2013
  • Table 61: Biogen Idec's CD Portfolio Assessment, 2013
  • Table 62: Biogen Idec's CD SWOT Analysis, 2013
  • Table 63: Takeda's CD Portfolio Assessment, 2013
  • Table 64: Takeda's CD SWOT Analysis, 2013
  • Table 65: ChemoCentryx's CD Portfolio Assessment, 2013
  • Table 66: ChemoCentryx's CD SWOT Analysis, 2013
  • Table 67: Global Sales Forecasts ($) for CD, 2012-2022
  • Table 68: Global CD Market - Drivers and Barriers, 2012-2022
  • Table 69: Sales Forecasts ($) for CD in the United States, 2012-2022
  • Table 70: Key Events Impacting Sales for CD in the US, 2012-2022
  • Table 71: CD Market in the US - Drivers and Barriers, 2012-2022
  • Table 72: Sales Forecasts ($) for CD in France, 2012-2022
  • Table 73: Key Events Impacting Sales for CD in France, 2012-2022
  • Table 74: CD Market in France - Drivers and Barriers, 2012-2022
  • Table 75: Sales Forecasts ($) for CD in Germany, 2012-2022
  • Table 76: Key Events Impacting Sales for CD in Germany, 2012-2022
  • Table 77: CD Market in Germany - Drivers and Barriers, 2012-2022
  • Table 78: Sales Forecasts ($) for CD in Italy, 2012-2022
  • Table 79: Key Events Impacting Sales for CD in Italy, 2012-2022
  • Table 80: CD Market in Italy - Drivers and Barriers, 2012-2022
  • Table 81: Sales Forecasts ($) for CD in Spain, 2012-2022
  • Table 82: Key Events Impacting Sales for CD in Spain, 2012-2022
  • Table 83: CD Market in Spain - Drivers and Barriers, 2012-2022
  • Table 84: Sales Forecasts ($) for CD in the UK, 2012-2022
  • Table 85: Key Events Impacting Sales for CD in the UK, 2012-2022
  • Table 86: CD Market in the UK - Drivers and Barriers, 2012-2022
  • Table 87: Sales Forecasts ($) for CD in Japan, 2012-2022
  • Table 88: Key Events Impacting Sales for CD in Japan, 2012-2022
  • Table 89: CD Market in Japan - Drivers and Barriers, 2012-2022
  • Table 90: Sales Forecasts ($) for CD in Canada, 2012-2022
  • Table 91: Key Events Impacting Sales for CD in Canada, 2012-2022
  • Table 92: CD Market in Canada - Drivers and Barriers, 2012-2022
  • Table 93: Sales Forecasts ($) for CD in China, 2012-2022
  • Table 94: Key Events Impacting Sales for CD in China, 2012-2022
  • Table 95: CD Market in China - Drivers and Barriers, 2012-2022
  • Table 96: Sales Forecasts ($) for CD in India, 2012-2022
  • Table 97: Key Events Impacting Sales for CD in India, 2012-2022
  • Table 98: CD Market in India - Drivers and Barriers, 2012-2022
  • Table 99: Key Launch Dates
  • Table 100: Key Patent Expiries
  • Table 101: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right)
  • Figure 2: Potential Biologic Drug Targets for CD
  • Figure 3: All Markets, Incident Cases of CD, Ages ≥10 Years, Men and Women, N, 2012-2022
  • Figure 4: All Markets, Incident Cases of CD, by Age, Men and Women, N, 2012
  • Figure 5: All Markets, Incident Cases of CD, by Sex, Ages ≥10 Years, N, 2012
  • Figure 6: All Markets, Age-Standardized Incidence Rate of CD, Ages ≥10 Years, Men and Women, 2012
  • Figure 7: All Markets, Prevalent Cases of CD, Ages ≥10 Years, Men and Women, N, 2012-2022
  • Figure 8: All Markets, Prevalent Cases of CD, by Age, Men and Women, N, 2012
  • Figure 9: All Markets, Prevalent Cases of CD, by Sex, Ages ≥10 Years, N, 2012
  • Figure 10: All Markets, Age-Standardized Prevalence of CD, Ages ≥10 Years, Men and Women, 2012
  • Figure 11: Patient Care Path for CD
  • Figure 12: CD Therapeutics - Clinical Trials by Country, 2013
  • Figure 13: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022
  • Figure 14: Company Portfolio Gap Analysis in CD, 2012-2022
  • Figure 15: Global Sales for CD by Region, 2012-2022
  • Figure 16: Sales for CD in the US by Drug Class, 2012-2022
  • Figure 17: Sales for CD in France by Drug Class, 2012-2022
  • Figure 18: Sales for CD in Germany by Drug Class, 2012-2022
  • Figure 19: Sales for CD in Italy by Drug Class, 2012-2022
  • Figure 20: Sales for CD in Spain by Drug Class, 2012-2022
  • Figure 21: Sales for CD in the UK by Drug Class, 2012-2022
  • Figure 22: Sales for CD in Japan by Drug Class, 2012-2022
  • Figure 23: Sales for CD in Canada by Drug Class, 2012-2022
  • Figure 24: Sales for CD in China by Drug Class, 2012-2022
  • Figure 25: Sales for CD in India by Drug Class, 2012-2022
Back to Top